Remibrutinib

Phase 3Active

1 views this week 0 watching⚡ Active

Interest: 44/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Chronic Inducible Urticaria

Conditions

Chronic Inducible Urticaria

Trial Timeline

Dec 7, 2023 → Jun 15, 2029

NCT ID

NCT05976243

About Remibrutinib

Remibrutinib is a phase 3 stage product being developed by Novartis for Chronic Inducible Urticaria. The current trial status is active. This product is registered under clinical trial identifier NCT05976243. Target conditions include Chronic Inducible Urticaria.

What happened to similar drugs?

20 of 20 similar drugs in Chronic Inducible Urticaria were approved

Approved (20) Terminated (3) Active (0)

✅Pegasys® + Pegasys®Chugai PharmaceuticalApproved

✅Telmisartan/Rosuvastatin 40/10mg + Telmisartan 40mgYuhanApproved

✅placebo + aspirin + clopidogrel + aspirin OR prasugrel + aspirinDaiichi SankyoApproved

✅alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved

✅alefaceptAstellas PharmaApproved

✅AlefaceptAstellas PharmaApproved

✅lysozyme 90 mg + PlaceboEisaiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05170724	Pre-clinical	Active	—	—	Chronic Spontaneous Urticaria
NCT07456891	Phase 3	Recruiting	Apr 10, 2026	Jan 30, 2033	Indication of the Parent Protocol
NCT07032272	Phase 1	Completed	Jul 23, 2025	Oct 14, 2025	Autoimmune and Chronic Inflammatory Diseases
NCT05976243	Phase 3	Active	Dec 7, 2023	Jun 15, 2029	Chronic Inducible Urticaria

Competing Products

20 competing products in Chronic Inducible Urticaria

See all competitors

Product	Company	Stage	Hype Score
Levofloxacin 500	Dr. Reddy's Laboratories	Pre-clinical	23
mRNA-0184	Moderna	Phase 1	0
Lubiprostone + Lubiprostone + Placebo	Dr. Reddy's Laboratories	Phase 3	37
macitentan 10 mg	BML, Inc.	Phase 3	32
KPL-716 + Placebo	Kiniksa Pharmaceuticals	Phase 2	29
TERN-701	Terns Pharmaceuticals	Phase 1/2	36
Fludarabine + Cyclophosphamide + PRGN-3007	Precigen	Phase 1	23
LY3556050 + Placebo	Eli Lilly	Phase 2	35
THB001	Third Harmonic Bio	Phase 1	11
Briquilimab	Jasper Therapeutics	Phase 1/2	26
Briquilimab	Jasper Therapeutics	Phase 1/2	14
Briquilimab	Jasper Therapeutics	Phase 2	29
Empagliflozin + Matching placebo	Eli Lilly	Phase 3	40
LY3461767 + Placebo	Eli Lilly	Phase 1	29
Pirtobrutinib + Venetoclax + Rituximab	Eli Lilly	Phase 3	44
LY3526318 + Placebo	Eli Lilly	Phase 2	35
Pirtobrutinib	Eli Lilly	Phase 2	42
Ibrutinib + LY3214996	Eli Lilly	Phase 1	21
Pirtobrutinib + Acalabrutinib	Eli Lilly	Phase 2	27
LYR-210	Lyra Therapeutics	Phase 2	25